Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.
暂无分享,去创建一个
A. Telenti | P. Sudre | P Sudre | R. Martínez | A Telenti | F Bally | R Martinez | S Peters | S. Peters | F. Bally | Solange Peters | Raquel Martínez
[1] H. Varmus,et al. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression , 1988, Nature.
[2] B Clotet,et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. , 1998, JAMA.
[3] F. Mammano,et al. Resistance-Associated Loss of Viral Fitness in Human Immunodeficiency Virus Type 1: Phenotypic Analysis of Protease andgag Coevolution in Protease Inhibitor-Treated Patients , 1998, Journal of Virology.
[4] J. Falloon,et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites , 1997, Journal of virology.
[5] D. Lamarre,et al. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors , 1996, Journal of virology.
[6] D. Lamarre,et al. Novel Gag-Pol Frameshift Site in Human Immunodeficiency Virus Type 1 Variants Resistant to Protease Inhibitors , 1998, Journal of Virology.
[7] B. Larder. Mechanisms of HIV-1 drug resistance. , 2001, AIDS.
[8] A. Telenti,et al. Virological and immunological characteristics of HIV treatment failure , 2000, AIDS.
[9] C. Hutchison,et al. Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid. , 1991, The Journal of biological chemistry.
[10] D. Lamarre,et al. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors , 1997, Journal of virology.
[11] D. Burke,et al. Phylogenetic analysis of gag genes from 70 international HIV‐1 isolates provides evidence for multiple genotypes , 1993, AIDS.
[12] D. Ho,et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir , 1996, Nature Medicine.
[13] J. Mellors,et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor , 1996, Journal of virology.
[14] F. Mammano,et al. Loss of Viral Fitness Associated with Multiple Gag and Gag-Pol Processing Defects in Human Immunodeficiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors In Vivo , 1998, Journal of Virology.
[15] Dale J. Kempf,et al. In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants with Increased Resistance to ABT-378, a Novel Protease Inhibitor , 1998, Journal of Virology.
[16] J. Fantini,et al. Mutations in HIV-1 gag cleavage sites and their association with protease mutations. , 2001, AIDS.